secwatch.observer — SEC 8-K summary
======================================

Issuer:     Natera, Inc. (NTRA)
CIK:        0001604821
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001104659-23-087265
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Natera Q2 revenue $261.4M (+31.9% YoY); net loss narrows; raises FY 2023 guidance
--------------------------------------------------------------------------------

- Total revenue $261.4M, up 31.9% YoY; product revenue $258.3M (+32.7%).
- Net loss $110.8M ($0.97/shr) vs loss $145.2M ($1.50/shr) YoY; operating loss $112.4M.
- Tests processed 617,200 (+23.5% YoY); oncology tests 83,500 (+88.9% YoY).
- Raised FY 2023 revenue guidance to $1.015B-$1.035B vs prior $995M-$1.015B.
- Won litigation: $19.35M damages from ArcherDX/Invitae; CareDx damages reduced to $0.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604821/000110465923087265/0001104659-23-087265-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604821/000110465923087265/tm2322356d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-087265

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer